[Clinical sequelae of genetically determined polymorphisms of drug oxidation].
Orzechowska-Juzwenko
K
K
Katedry i Zakładu Farmakologii Klinicznej AM, Wrocławiu.
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics; D014150:Antipsychotic Agents / Q000493:pharmacokinetics; D004347:Drug Interactions; D005006:Ethnicity / Q000235:genetics; D006801:Humans; D010084:Oxidation-Reduction; D010599:Pharmacokinetics; D010641:Phenotype; D011110:Polymorphism, Genetic
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D014150:Antipsychotic Agents
Kliniczne nastepstwa genetycznie uwarunkowanego polimorfizmu utleniania leków.